Karlin-Neumann, George, PhD

Director of Scientific Affairs for Bio-Rad's Digital Biology Center

Dr. George Karlin-Neumann is a molecular geneticist, biotechnologist and entrepreneur. He co-founded ParAllele BioScience, a successful high throughput genomics company, out of the Stanford Genome Technology Center in 2001. Dr.Karlin-Neumann joined Affymetrix in 2005 after it acquired ParAllele for its highly multiplexed genetics and genomics assay technology. There he continued developing state-of-the-art assays for cancer copy number variation in FFPE samples and for pharmacogenomic profiling, the latter used for population stratification in clinical trials for drug development. Since 2009, he consulted for local and international genetics and molecular tools start-ups until joining QuantaLife in 2010, first as Sr. Director of Molecular Diagnostics, then as Sr. Director of Assay Development. After Quantalife’s acquisition by Bio-Rad Laboratories in 2011 and its re-naming as The Digital Biology Center, he transitioned to his current role there as Director of Scientific Affairs. He was trained in molecular genetics at UCLA, where he received his PhD in 1990 for innovative studies using conditional lethal screens to identify mutants in light-activated nuclear gene transcription. He subsequently adapted this approach to the genetic study of mechanosensory signaling in Arabidopsis during a postdoctoral fellowship with Dr. Ronald Davis in the Stanford Biochemistry Department. Prior to leaving Stanford, he spent five years as the co-PI on an NSF-funded Plant Sensory Network Consortium grant where he developed and disseminated DNA microarray technology to partnering institutions.

Listen to an interview with George